Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
There are promising GLP1 Receptor Agonists on the horizon, both in injection form and pill based forms. MariTide is one of them (formerly known as AMG-133) and Orforglipron is another:
GLP1.Guide Staff
GLP1.Guide Staff
We've covered both of these before, but what's important/interesting is that there has just been an update on both of these drugs at the ADA 85th Science Sessions conference:
While the data from some of the trials has not fully been released, the presentation and press release serve as a key check into the progress on these drugs, and how effective they are.
The GLP1 landscape is quite crowded these days, but MariTide and Orforglipron are some of the most promising upcomers so we took some time to get caught up.
What's changed with MariTide (AMG-133)?
Remember that Maritide is actually taken once monthly – a departure from other popular GLP1s which are usually injected weekly.
At the conference full results from part one of a Phase 2 study of MariTide were announced:
- 20% average weight loss (+17% compared to placebo) for people who did not have type 2 diabetes
- No Plateau after 1 year
- Up to 2.2% reduction in Hba1c
- Participants were taken from 21mg to 35mg to 70mg dosages
Jay Bradner, a Medical Doctor (MD) and executive Vice President (VP) of medical research at Amgen noted the usefulness of being able to reduce injections to once a month:
MariTide's monthly or less frequent dosing has the potential to improve adherence and long-term weight control, providing the opportunity to optimize health outcomes for people living with obesity, Type 2 diabetes and related conditions.
We think this is a possible game changer for the field – and a huge reduction in the ecological impact of production, use and disposal of injection pens.
There were also no new negative side effects, which is always great to read.
Gastrointestinal events were predominantly limited to initial dosing and less frequent when dose escalation was used without compromising efficacy.
The idea that less gastrointestinal problems were reported when doses went up is a good sign. This is quite different from the usual case of most GLP1s today in which people increase dosage and run into more gastrointestinal problems (somewhat intuitively).
Amgen also published an update themselves, which you can read through:
If you'd like to go straight to the details, see the published data in the New England Journal of Medicine:
To track the trials yourself, check out the clinical trials page:
What's changed with Orforglipron?
The ACHIEVE-1 Phase 3 Trial is an ongoing trial which has been taking place across US, China, India, Japan and Mexico. The updates delivered at the Science Sessions conference also showed fantastic progress for this completely orally administered GLP1:
- 559 participants with type 2 diabetes
- HbA1C lowered by 1.3% to 1.6%
- Dosages went from 3mg to 12mg to 36mg
Remember, Orforglipron is a once daily pill. While there weren't great results for weight loss that were announced, Orforglipron does still contribute to weight loss:
GLP1.Guide Staff
The focus here was on HbA1c, and it did quite well, along with having very wide usability due to it's ease of use.
Orforglipron is also a game changer (though in a different way) than MariTide and is also being eagerly awaited by many.
To follow the trial directly use the link below:
